Recent Insider Selling: JPMorgan Chase (NYSE:JPM), Micron Technology (NASDAQ:MU), Gilead Sciences (NASDAQ:GILD), Arena Pharmaceuticals (NASDAQ:ARNA)

Technology Stocks News 18

JPMorgan Chase & Co. (NYSE:JPM) EVP Gordon Smith sold 71,952 shares of the stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $54.91, for a total value of $3,950,884.32. Following the transaction, the executive vice president now directly owns 143,905 shares of the company’s stock, valued at approximately $7,901,824. JPMorgan Chase & Co. (NYSE:JPM) stock performance was 0.84% in last session and finished the day at $55.26. Traded volume was 27.05million shares in the last session and the average volume of the stock remained 20.13million shares. The beta of the stock remained 1.71. JPMorgan Chase & Co. (NYSE:JPM) insider ownership is 0.10%.

Micron Technology Inc (NYSE:MU) CEO Dermot Mark Durcan sold 200,000 shares of the company’s stock on the open market in a transaction that occurred on Tuesday, April 15th. The shares were sold at an average price of $21.90, for a total value of $4,380,000.00. Micron Technology, Inc. (NASDAQ:MU) rose 1.40 percent to $22.48 Wednesday on volume of 21.62million shares. The intra-day range of the stock was $22.00 to $22.57. Micron Technology, Inc. (NASDAQ:MU) has a market capitalization of $24.06billion.

Gilead Sciences Inc (NASDAQ:GILD) EVP Norbert W. Bischofberger sold 90,000 shares of the stock on the open market in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $67.03, for a total transaction of $6,032,700.00. Gilead Sciences, Inc. (NASDAQ:GILD)’s stock on Apr 16, 2014 reported a increase of 1.63% to the closing price of $69.28. Its fifty two weeks range is $46.70 -$84.88. The total market capitalization recorded $106.54billion. The overall volume in the last trading session was 17.27million shares. In its share capital, GILD has 1.54billion outstanding shares.

Arena Pharmaceuticals Inc (NASDAQ:ARNA) Director Tina Susan Nova sold 35,000 shares of Arena Pharmaceuticals stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $6.22, for a total transaction of $217,700.00. Following the sale, the director now directly owns 18,728 shares of the company’s stock, valued at approximately $116,488. On Wednesday, shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) dropped -0.79% to close the day at $6.30. Company return on investment (ROI) is -1390% and its monthly performance is recorded as -4.55%. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) quarterly revenue growth is -13.82%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone